181 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Clinical Pharmacology Audio PeerVoice

    • Science
    • 5.0 • 3 Ratings

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Step-by-Step: Setting a Course for Long-Term Control of Type 2 Diabetes With GLP-1 RAs

    Step-by-Step: Setting a Course for Long-Term Control of Type 2 Diabetes With GLP-1 RAs

    Visit https://www.peervoice.com/XDM860 to view the entire programme with slides. After completing “Step-by-Step: Setting a Course for Long-Term Control of Type 2 Diabetes With GLP-1 RAs”, participants will be able to: Describe the rationale for GLP-1 receptor agonists (RAs) in the management of patients with type 2 diabetes (T2DM) as discussed in recent clinical guidelines; Evaluate the outcomes that will help achieve patient behaviour, such as weight loss and long-term benefits of controlling T2DM; Apply strategies to help patients overcome barriers to achieving long-term control of T2DM, including adherence to therapy and lifestyle changes.

    • 21 min
    Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC

    Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC

    Visit https://www.peervoice.com/VVA860 to view the entire programme with slides. After completing “Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC”, participants will be able to: Describe the unmet needs for patients with advanced NSCLC and how checkpoint inhibitors can address these challenges; Evaluate the most recent clinical evidence for current and emerging checkpoint inhibitors in the first-line management of advanced NSCLC with high PD-L1 expression; Discuss how emerging data may impact the treatment algorithm for patients with advanced NSCLC and high PD-L1 expression.

    • 29 min
    Biologics and Beyond in Atopic Dermatitis: Emerging Targets and How They Work

    Biologics and Beyond in Atopic Dermatitis: Emerging Targets and How They Work

    Visit https://www.peervoice.com/ZFT860 to view the entire programme with slides. After completing “Biologics and Beyond in Atopic Dermatitis: Emerging Targets and How They Work”, participants will be able to: Define the key goals of therapy for patients with moderate-to-severe atopic dermatitis (AD); Describe the limitations of current biologic therapies; Identify the therapeutic targets that are being assessed in clinical development for moderate-to-severe AD.

    • 22 min
    Why Combination Therapies and Why Now? The Rationale and Role of GLP-1 RAs and Insulin

    Why Combination Therapies and Why Now? The Rationale and Role of GLP-1 RAs and Insulin

    Visit https://www.peervoice.com/WBG860 to view the entire programme with slides. After completing “Why Combination Therapies and Why Now? The Rationale and Role of GLP-1 RAs and Insulin”, participants will be able to: Explain the rationale for combining GLP-1 receptor agonists (RAs) and basal insulin for patients with T2DM, based on mechanisms of action and recent guidelines; Evaluate the efficacy of combination therapy of GLP-1 RA and basal insulin on HbA1c, fasting and postprandial glucose, and other key glycaemic control measures; Discuss the most recent safety data for GLP-1 RAs, with a focus on hypoglycaemia, weight gain, and tolerability; Apply clinical data for combination therapy in the management of patients with T2DM in daily practice.

    • 32 min
    Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy

    Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy

    Visit https://www.peervoice.com/HJS860 to view the entire programme with slides. After completing “Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy”, participants will be able to: Characterise the incidence and impact of colchicine resistance among patients with FMF; Understand disease burden from the perspective of the patient; Analyse the long-term clinical and quality-of-life (QoL) data for anti–IL-1 therapy in colchicine-resistant FMF.

    • 59 min
    Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer

    Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer

    Visit https://www.peervoice.com/SSK860 to view the entire programme with slides. After completing “Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer”, participants will be able to: Describe the importance of first-line maintenance therapy for patients with advanced ovarian cancer: Differentiate among PARP inhibitors in terms of mutation status, dosing and administration, and adverse events; Formulate optimal personalised treatment plans taking into account individual- and disease-related factors for patients with advanced ovarian cancer.

    • 27 min

Customer Reviews

5.0 out of 5
3 Ratings

3 Ratings

Top Podcasts In Science

Listeners Also Subscribed To